We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation

2023-09-05 Interview with Redeye

Redeye interviews CEO Göran Forsberg about Cantargia's expanded clinical pipeline and start of treatment in second program, CAN10, for autoimmune diseases

Watch the interview here

2023-07-06 Interview with Redeye

Redeye interviews CEO Göran Forsberg about the positive announcement that protection for nadunolimab and several variant antibodies remains after oppositions against one of Cantargia's patents

Watch the interview here

2023-05-23 CEO speech AGM 2023

Watch the CEO speech here